Download PDFPDF

Lung cancer: advances in treatment
S87 Delivered dose intensity of gemcitabine 1250 mg/m2 with cisplatin at 80 mg/m2 (GC80) and 50 mg/m2 (GC50) and carboplatin AUC 6 (GCb6) in a phase III trial of advanced non-small cell lung cancer (NSCLC): correlations with clinical outcomes

Share this article

Click the icon of the social media platform on which you would like to share this article.

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
Enter multiple addresses on separate lines or separate them with commas.
(Your Name) has forwarded a page to you from Thorax
(Your Name) thought you would like to see this page from the Thorax web site.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.